This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Croft, S. L.
Right arrow Articles by Fairlamb, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Croft, S. L.
Right arrow Articles by Fairlamb, A. H.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Leishmaniasis

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, January 2006, p. 111-126, Vol. 19, No. 1
0893-8512/06/$08.00+0     doi:10.1128/CMR.19.1.111-126.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Drug Resistance in Leishmaniasis

Simon L. Croft,1* Shyam Sundar,2 and Alan H. Fairlamb3

Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom,1 Infectious Diseases Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221 005, India,2 Division of Biological Chemistry and Molecular Biology, Wellcome Trust Biocentre, School of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, United Kingdom3

Leishmaniasis is a complex disease, with visceral and cutaneous manifestations, and is caused by over 15 different species of the protozoan parasite genus Leishmania. There are significant differences in the sensitivity of these species both to the standard drugs, for example, pentavalent antimonials and miltefosine, and those on clinical trial, for example, paromomycin. Over 60% of patients with visceral leishmaniasis in Bihar State, India, do not respond to treatment with pentavalent antimonials. This is now considered to be due to acquired resistance. Although this class of drugs has been used for over 60 years for leishmaniasis treatment, it is only in the past 2 years that the mechanisms of action and resistance have been identified, related to drug metabolism, thiol metabolism, and drug efflux. With the introduction of new therapies, including miltefosine in 2002 and paromomycin in 2005-2006, it is essential that there be a strategy to prevent the emergence of resistance to new drugs; combination therapy, monitoring of therapy, and improved diagnostics could play an essential role in this strategy.

* Corresponding author. Present address: Drugs for Neglected Diseases Initiative, 1 Place Saint-Gervais, CH-1201 Geneva, Switzerland. Phone: 0041 (0)22 906 9238. Fax: 0041 (0)22 906 9231. E-mail: scroft{at}dndi.org.

Clinical Microbiology Reviews, January 2006, p. 111-126, Vol. 19, No. 1
0893-8512/06/$08.00+0     doi:10.1128/CMR.19.1.111-126.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Inocencio da Luz, R., Vermeersch, M., Dujardin, J.-C., Cos, P., Maes, L. (2009). In Vitro Sensitivity Testing of Leishmania Clinical Field Isolates: Preconditioning of Promastigotes Enhances Infectivity for Macrophage Host Cells. Antimicrob. Agents Chemother. 53: 5197-5203 [Abstract] [Full Text]  
  • Furnkranz, U., Nagl, M., Gottardi, W., Matt, U., Aspock, H., Walochnik, J. (2009). N-Chlorotaurine shows high in vitro activity against promastigotes and amastigotes of Leishmania species. J Med Microbiol 58: 1298-1302 [Abstract] [Full Text]  
  • Vermeersch, M., da Luz, R. I., Tote, K., Timmermans, J.-P., Cos, P., Maes, L. (2009). In Vitro Susceptibilities of Leishmania donovani Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific Differences. Antimicrob. Agents Chemother. 53: 3855-3859 [Abstract] [Full Text]  
  • del Rosal, T., Artigao, F. B., Miguel, M. J. G., de Lucas, R., del Castillo, F. (2009). Successful Treatment of Childhood Cutaneous Leishmaniasis with Liposomal Amphotericin B: Report of Two Cases. J Trop Pediatr 0: fmp073v1-fmp073 [Abstract] [Full Text]  
  • Holloway, G. A., Charman, W. N., Fairlamb, A. H., Brun, R., Kaiser, M., Kostewicz, E., Novello, P. M., Parisot, J. P., Richardson, J., Street, I. P., Watson, K. G., Baell, J. B. (2009). Trypanothione Reductase High-Throughput Screening Campaign Identifies Novel Classes of Inhibitors with Antiparasitic Activity. Antimicrob. Agents Chemother. 53: 2824-2833 [Abstract] [Full Text]  
  • Banerjee, S., Ghosh, J., Sen, S., Guha, R., Dhar, R., Ghosh, M., Datta, S., Raychaudhury, B., Naskar, K., Haldar, A. K., Lal, C. S., Pandey, K., Das, V. N. R., Das, P., Roy, S. (2009). Designing Therapies against Experimental Visceral Leishmaniasis by Modulating the Membrane Fluidity of Antigen-Presenting Cells. Infect. Immun. 77: 2330-2342 [Abstract] [Full Text]  
  • Maurer-Cecchini, A., Decuypere, S., Chappuis, F., Alexandrenne, C., De Doncker, S., Boelaert, M., Dujardin, J.-C., Loutan, L., Dayer, J.-M., Tulliano, G., Arevalo, J., Llanos-Cuentas, A., Chizzolini, C. (2009). Immunological Determinants of Clinical Outcome in Peruvian Patients with Tegumentary Leishmaniasis Treated with Pentavalent Antimonials. Infect. Immun. 77: 2022-2029 [Abstract] [Full Text]  
  • Hunter, W. N. (2009). Structure-based Ligand Design and the Promise Held for Antiprotozoan Drug Discovery. J. Biol. Chem. 284: 11749-11753 [Abstract] [Full Text]  
  • Charret, K. S., Rodrigues, R. F., Bernardino, A. M. R., Gomes, A. O., Carvalho, A. V., Canto-Cavalheiro, M. M., Leon, L., Amaral, V. F. (2009). Effect of Oral Treatment with Pyrazole Carbohydrazide Derivatives against Murine Infection by Leishmania amazonensis. Am J Trop Med Hyg 80: 568-573 [Abstract] [Full Text]  
  • Leprohon, P., Legare, D., Raymond, F., Madore, E., Hardiman, G., Corbeil, J., Ouellette, M. (2009). Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum. Nucleic Acids Res 37: 1387-1399 [Abstract] [Full Text]  
  • Dunning, N. (2009). Leishmania vaccines: from leishmanization to the era of DNA technology. Bioscience Horizons 2: 73-82 [Abstract] [Full Text]  
  • Kumar, D., Kulshrestha, A., Singh, R., Salotra, P. (2009). In Vitro Susceptibility of Field Isolates of Leishmania donovani to Miltefosine and Amphotericin B: Correlation with Sodium Antimony Gluconate Susceptibility and Implications for Treatment in Areas of Endemicity. Antimicrob. Agents Chemother. 53: 835-838 [Abstract] [Full Text]  
  • Boggild, A. K., Miranda-Verastegui, C., Espinosa, D., Arevalo, J., Martinez-Medina, D., Llanos-Cuentas, A., Low, D. E. (2008). Optimization of Microculture and Evaluation of Miniculture for the Isolation of Leishmania Parasites from Cutaneous Lesions in Peru. Am J Trop Med Hyg 79: 847-852 [Abstract] [Full Text]  
  • Fernandes Rodrigues, J. C., Concepcion, J. L., Rodrigues, C., Caldera, A., Urbina, J. A., de Souza, W. (2008). In Vitro Activities of ER-119884 and E5700, Two Potent Squalene Synthase Inhibitors, against Leishmania amazonensis: Antiproliferative, Biochemical, and Ultrastructural Effects. Antimicrob. Agents Chemother. 52: 4098-4114 [Abstract] [Full Text]  
  • Castanys-Munoz, E., Perez-Victoria, J. M., Gamarro, F., Castanys, S. (2008). Characterization of an ABCG-Like Transporter from the Protozoan Parasite Leishmania with a Role in Drug Resistance and Transbilayer Lipid Movement. Antimicrob. Agents Chemother. 52: 3573-3579 [Abstract] [Full Text]  
  • Martinez-Rojano, H., Mancilla-Ramirez, J., Quinonez-Diaz, L., Galindo-Sevilla, N. (2008). Activity of Hydroxyurea against Leishmania mexicana. Antimicrob. Agents Chemother. 52: 3642-3647 [Abstract] [Full Text]  
  • Vince, J. E., Tull, D. L., Spurck, T., Derby, M. C., McFadden, G. I., Gleeson, P. A., Gokool, S., McConville, M. J. (2008). Leishmania Adaptor Protein-1 Subunits Are Required for Normal Lysosome Traffic, Flagellum Biogenesis, Lipid Homeostasis, and Adaptation to Temperatures Encountered in the Mammalian Host. Eukaryot Cell 7: 1256-1267 [Abstract] [Full Text]  
  • Fyfe, P. K., Oza, S. L., Fairlamb, A. H., Hunter, W. N. (2008). Leishmania Trypanothione Synthetase-Amidase Structure Reveals a Basis for Regulation of Conflicting Synthetic and Hydrolytic Activities. J. Biol. Chem. 283: 17672-17680 [Abstract] [Full Text]  
  • Alvar, J., Aparicio, P., Aseffa, A., Den Boer, M., Canavate, C., Dedet, J.-P., Gradoni, L., Ter Horst, R., Lopez-Velez, R., Moreno, J. (2008). The Relationship between Leishmaniasis and AIDS: the Second 10 Years. Clin. Microbiol. Rev. 21: 334-359 [Abstract] [Full Text]  
  • Wyllie, S., Vickers, T. J., Fairlamb, A. H. (2008). Roles of Trypanothione S-Transferase and Tryparedoxin Peroxidase in Resistance to Antimonials. Antimicrob. Agents Chemother. 52: 1359-1365 [Abstract] [Full Text]  
  • Mookerjee Basu, J., Mookerjee, A., Banerjee, R., Saha, M., Singh, S., Naskar, K., Tripathy, G., Sinha, P. K., Pandey, K., Sundar, S., Bimal, S., Das, P. K., Choudhuri, S. K., Roy, S. (2008). Inhibition of ABC Transporters Abolishes Antimony Resistance in Leishmania Infection. Antimicrob. Agents Chemother. 52: 1080-1093 [Abstract] [Full Text]  
  • El Fadili, K., Imbeault, M., Messier, N., Roy, G., Gourbal, B., Bergeron, M., Tremblay, M. J., Legare, D., Ouellette, M. (2008). Modulation of Gene Expression in Human Macrophages Treated with the Anti-Leishmania Pentavalent Antimonial Drug Sodium Stibogluconate. Antimicrob. Agents Chemother. 52: 526-533 [Abstract] [Full Text]  
  • Collazos, J. (2008). Comment on: Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 61: 466-467 [Full Text]  
  • Boggild, A. K., Miranda-Verastegui, C., Espinosa, D., Arevalo, J., Adaui, V., Tulliano, G., Llanos-Cuentas, A., Low, D. E. (2007). Evaluation of a Microculture Method for Isolation of Leishmania Parasites from Cutaneous Lesions of Patients in Peru. J. Clin. Microbiol. 45: 3680-3684 [Abstract] [Full Text]  
  • Saha, S., Mondal, S., Ravindran, R., Bhowmick, S., Modak, D., Mallick, S., Rahman, M., Kar, S., Goswami, R., Guha, S. K., Pramanik, N., Saha, B., Ali, N. (2007). IL-10- and TGF-beta-Mediated Susceptibility in Kala-azar and Post-kala-azar Dermal Leishmaniasis: The Significance of Amphotericin B in the Control of Leishmania donovani Infection in India. J. Immunol. 179: 5592-5603 [Abstract] [Full Text]  
  • Molina, I., Falco, V., Crespo, M., Riera, C., Ribera, E., Curran, A., Carrio, J., Diaz, M., Villar del Saz, S., Fisa, R., Lopez-Chejade, P., Ocana, I., Pahissa, A. (2007). Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 60: 837-842 [Abstract] [Full Text]  
  • Sen, R., Bandyopadhyay, S., Dutta, A., Mandal, G., Ganguly, S., Saha, P., Chatterjee, M. (2007). Artemisinin triggers induction of cell-cycle arrest and apoptosis in Leishmania donovani promastigotes. J Med Microbiol 56: 1213-1218 [Abstract] [Full Text]  
  • Coelho, A. C., Messier, N., Ouellette, M., Cotrim, P. C. (2007). Role of the ABC Transporter PRP1 (ABCC7) in Pentamidine Resistance in Leishmania Amastigotes. Antimicrob. Agents Chemother. 51: 3030-3032 [Abstract] [Full Text]  
  • LLANOS-CUENTAS, A., ECHEVARRIA, J., SEAS, C., CHANG, E., CRUZ, M., ALVAREZ, E., ROSALES, E., CAMPOS, P., BRYCESON, A. (2007). PARENTERAL AMINOSIDINE IS NOT EFFECTIVE FOR PERUVIAN MUCOCUTANEOUS LEISHMANIASIS. Am J Trop Med Hyg 76: 1128-1131 [Abstract] [Full Text]  
  • Llull, D., Rivas, L., Garcia, E. (2007). In Vitro Bactericidal Activity of the Antiprotozoal Drug Miltefosine against Streptococcus pneumoniae and Other Pathogenic Streptococci. Antimicrob. Agents Chemother. 51: 1844-1848 [Abstract] [Full Text]  
  • Luque-Ortega, J. R., Rivas, L. (2007). Miltefosine (Hexadecylphosphocholine) Inhibits Cytochrome c Oxidase in Leishmania donovani Promastigotes. Antimicrob. Agents Chemother. 51: 1327-1332 [Abstract] [Full Text]  
  • Ashutosh, , Sundar, S., Goyal, N. (2007). Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 56: 143-153 [Abstract] [Full Text]  
  • Vergnes, B., Gourbal, B., Girard, I., Sundar, S., Drummelsmith, J., Ouellette, M. (2007). A Proteomics Screen Implicates HSP83 and a Small Kinetoplastid Calpain-related Protein in Drug Resistance in Leishmania donovani Clinical Field Isolates by Modulating Drug-induced Programmed Cell Death. Mol. Cell. Proteomics 6: 88-101 [Abstract] [Full Text]  
  • CALVOPINA, M., GOMEZ, E. A., SINDERMANN, H., COOPER, P. J., HASHIGUCHI, Y. (2006). RELAPSE OF NEW WORLD DIFFUSE CUTANEOUS LEISHMANIASIS CAUSED BY LEISHMANIA (LEISHMANIA) MEXICANA AFTER MILTEFOSINE TREATMENT. Am J Trop Med Hyg 75: 1074-1077 [Abstract] [Full Text]  
  • Serrano-Martin, X., Payares, G., Mendoza-Leon, A. (2006). Glibenclamide, a Blocker of K+ATP Channels, Shows Antileishmanial Activity in Experimental Murine Cutaneous Leishmaniasis. Antimicrob. Agents Chemother. 50: 4214-4216 [Abstract] [Full Text]  
  • Sernee, M. F., Ralton, J. E., Dinev, Z., Khairallah, G. N., O'Hair, R. A., Williams, S. J., McConville, M. J. (2006). Leishmania beta-1,2-mannan is assembled on a mannose-cyclic phosphate primer. Proc. Natl. Acad. Sci. USA 103: 9458-9463 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»